Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of “Moderate Buy” from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $40.80.

A number of research firms have recently issued reports on GMAB. Wall Street Zen upgraded shares of Genmab A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, September 26th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Genmab A/S in a report on Wednesday. Truist Financial lifted their price objective on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a report on Tuesday, July 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd.

Genmab A/S Stock Performance

Shares of GMAB opened at $32.72 on Thursday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $33.63. The firm’s 50 day moving average price is $27.51 and its two-hundred day moving average price is $23.13. The firm has a market cap of $21.01 billion, a P/E ratio of 16.44, a PEG ratio of 1.85 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

A number of institutional investors have recently added to or reduced their stakes in the company. CWM LLC increased its holdings in Genmab A/S by 28.3% during the third quarter. CWM LLC now owns 2,306 shares of the company’s stock worth $71,000 after buying an additional 509 shares during the last quarter. Aaron Wealth Advisors LLC acquired a new position in Genmab A/S during the third quarter worth $228,000. GAMMA Investing LLC increased its holdings in Genmab A/S by 55.4% during the third quarter. GAMMA Investing LLC now owns 2,982 shares of the company’s stock worth $91,000 after buying an additional 1,063 shares during the last quarter. Osaic Holdings Inc. increased its holdings in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after buying an additional 440 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock worth $1,947,000 after buying an additional 81,434 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.